S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
His system isolated NVIDIA - Here's His Next Buy. (Ad)
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
His system isolated NVIDIA - Here's His Next Buy. (Ad)
Speaker McCarthy is giving hard-right Republicans what they want. But it never seems to be enough.
At UN, African leaders say enough is enough: They must be partnered with, not sidelined
His system isolated NVIDIA - Here's His Next Buy. (Ad)
Leading Egyptian opposition politician targeted with spyware, researchers find
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
His system isolated NVIDIA - Here's His Next Buy. (Ad)
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
His system isolated NVIDIA - Here's His Next Buy. (Ad)
Speaker McCarthy is giving hard-right Republicans what they want. But it never seems to be enough.
At UN, African leaders say enough is enough: They must be partnered with, not sidelined
His system isolated NVIDIA - Here's His Next Buy. (Ad)
Leading Egyptian opposition politician targeted with spyware, researchers find
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
His system isolated NVIDIA - Here's His Next Buy. (Ad)
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
His system isolated NVIDIA - Here's His Next Buy. (Ad)
Speaker McCarthy is giving hard-right Republicans what they want. But it never seems to be enough.
At UN, African leaders say enough is enough: They must be partnered with, not sidelined
His system isolated NVIDIA - Here's His Next Buy. (Ad)
Leading Egyptian opposition politician targeted with spyware, researchers find
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
His system isolated NVIDIA - Here's His Next Buy. (Ad)
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
His system isolated NVIDIA - Here's His Next Buy. (Ad)
Speaker McCarthy is giving hard-right Republicans what they want. But it never seems to be enough.
At UN, African leaders say enough is enough: They must be partnered with, not sidelined
His system isolated NVIDIA - Here's His Next Buy. (Ad)
Leading Egyptian opposition politician targeted with spyware, researchers find
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
NASDAQ:MRNS

Marinus Pharmaceuticals (MRNS) Stock Forecast, Price & News

$6.60
-0.15 (-2.22%)
(As of 09/22/2023 ET)
Compare
Today's Range
$6.57
$7.00
50-Day Range
$5.86
$10.89
52-Week Range
$3.46
$11.15
Volume
454,165 shs
Average Volume
788,191 shs
Market Capitalization
$334.03 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$21.50

Marinus Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.89 Rating Score
Upside/​Downside
225.8% Upside
$21.50 Price Target
Short Interest
Bearish
7.09% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.56
Upright™ Environmental Score
News Sentiment
0.59mentions of Marinus Pharmaceuticals in the last 14 days
Based on 15 Articles This Week
Insider Trading
Selling Shares
$131,258 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($2.56) to ($2.43) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.49 out of 5 stars

Medical Sector

146th out of 965 stocks

Pharmaceutical Preparations Industry

49th out of 456 stocks


MRNS stock logo

About Marinus Pharmaceuticals (NASDAQ:MRNS) Stock

Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential. It is developing ganaxolone for treating genetic epilepsy disorders, such as PCDH19-related epilepsy, and tuberous sclerosis complex. Marinus Pharmaceuticals, Inc. has license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc.; and collaboration agreement with Orion Corporation and Tenacia Biotechnology (Shanghai) Co., Ltd. The company was incorporated in 2003 and is headquartered in Radnor, Pennsylvania.

MRNS Price History

MRNS Stock News Headlines

WARNING: Mandatory U.S. Dollar Recall is Weeks Away
If you have any U.S. dollars in your bank account… You must see this shocking video exposing the government’s new plan to recall the U.S. dollar. According to Business Insider, this recall “could be imminent.” And if you don’t prepare now, you could end up holding a bunch of worthless U.S. dollars.
Marinus Pharmaceuticals (NASDAQ:MRNS) PT Raised to $21.00
66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
Marinus (MRNS) Receives a Buy from JMP Securities
H.C. Wainwright Sticks to Their Buy Rating for Marinus (MRNS)
See More Headlines
Receive MRNS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Marinus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

MRNS Company Calendar

Last Earnings
8/10/2023
Today
9/24/2023
Next Earnings (Estimated)
11/06/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MRNS
Employees
151
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$21.50
High Stock Price Forecast
$32.00
Low Stock Price Forecast
$9.00
Forecasted Upside/Downside
+225.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.89
Research Coverage
9 Analysts

Profitability

Net Income
$-19,820,000.00
Net Margins
-113.01%
Pretax Margin
-99.51%

Debt

Sales & Book Value

Annual Sales
$25.48 million
Book Value
$2.26 per share

Miscellaneous

Free Float
48,150,000
Market Cap
$334.03 million
Optionable
Optionable
Beta
1.35
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

  • Dr. Scott N. Braunstein M.D. (Age 60)
    CEO, Pres & Chairman
    Comp: $919.29k
  • Mr. Steven E. Pfanstiel C.M.A. (Age 49)
    M.B.A., COO, CFO & Treasurer
    Comp: $580.35k
  • Dr. Joseph Hulihan M.D. (Age 67)
    Chief Medical Officer
    Comp: $639.51k
  • Dr. Alex Aimetti Ph.D.
    Chief Scientific Officer
  • Ms. Sonya Weigle
    Sr. VP of Investor Relations, HR & Corp. Affairs
  • Ms. Martha E. Manning Esq. (Age 68)
    J. D., Sr. VP, Gen. Counsel & Sec.
  • Molly Cameron
    Director of Corp. Communications & Investor Relations
  • Dr. Kimberly A. McCormick Pharm.D.
    PharmD, Chief Regulatory & Quality Assurance Officer
  • Mr. Thomas J. Lyons
    Chief Bus. Officer
  • Ms. Christina Shafer (Age 47)
    Chief Commercial Officer













MRNS Stock - Frequently Asked Questions

Should I buy or sell Marinus Pharmaceuticals stock right now?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Marinus Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" MRNS shares.
View MRNS analyst ratings
or view top-rated stocks.

What is Marinus Pharmaceuticals' stock price forecast for 2023?

9 Wall Street research analysts have issued twelve-month price objectives for Marinus Pharmaceuticals' stock. Their MRNS share price forecasts range from $9.00 to $32.00. On average, they expect the company's stock price to reach $21.50 in the next twelve months. This suggests a possible upside of 225.8% from the stock's current price.
View analysts price targets for MRNS
or view top-rated stocks among Wall Street analysts.

How have MRNS shares performed in 2023?

Marinus Pharmaceuticals' stock was trading at $3.98 at the beginning of 2023. Since then, MRNS stock has increased by 65.8% and is now trading at $6.60.
View the best growth stocks for 2023 here
.

When is Marinus Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 6th 2023.
View our MRNS earnings forecast
.

How were Marinus Pharmaceuticals' earnings last quarter?

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) issued its quarterly earnings data on Thursday, August, 10th. The biopharmaceutical company reported ($0.61) earnings per share for the quarter, topping analysts' consensus estimates of ($0.76) by $0.15. The biopharmaceutical company had revenue of $6.08 million for the quarter, compared to analysts' expectations of $5.14 million. Marinus Pharmaceuticals had a negative net margin of 113.01% and a negative trailing twelve-month return on equity of 139.10%.

What ETFs hold Marinus Pharmaceuticals' stock?

ETFs with the largest weight of Marinus Pharmaceuticals (NASDAQ:MRNS) stock in their portfolio include Simplify Propel Opportunities ETF (SURI) and iShares Neuroscience and Healthcare ETF (IBRN).Invesco Dorsey Wright Healthcare Momentum ETF (PTH).

When did Marinus Pharmaceuticals' stock split?

Shares of Marinus Pharmaceuticals reverse split before market open on Wednesday, September 23rd 2020. The 1-4 reverse split was announced on Tuesday, September 22nd 2020. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, September 22nd 2020. An investor that had 100 shares of stock prior to the reverse split would have 25 shares after the split.

What other stocks do shareholders of Marinus Pharmaceuticals own?
What is Marinus Pharmaceuticals' stock symbol?

Marinus Pharmaceuticals trades on the NASDAQ under the ticker symbol "MRNS."

Who are Marinus Pharmaceuticals' major shareholders?

Marinus Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Suvretta Capital Management LLC (8.02%), BlackRock Inc. (7.71%), Jennison Associates LLC (3.69%), Point72 Asset Management L.P. (2.62%), Franklin Resources Inc. (2.61%) and Geode Capital Management LLC (1.87%). Insiders that own company stock include Christina Shafer, Martha E Manning, Scott Braunstein, Seth H Z Fischer and Steven Pfanstiel.
View institutional ownership trends
.

How do I buy shares of Marinus Pharmaceuticals?

Shares of MRNS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Marinus Pharmaceuticals' stock price today?

One share of MRNS stock can currently be purchased for approximately $6.60.

How much money does Marinus Pharmaceuticals make?

Marinus Pharmaceuticals (NASDAQ:MRNS) has a market capitalization of $334.03 million and generates $25.48 million in revenue each year. The biopharmaceutical company earns $-19,820,000.00 in net income (profit) each year or ($0.15) on an earnings per share basis.

How many employees does Marinus Pharmaceuticals have?

The company employs 151 workers across the globe.

How can I contact Marinus Pharmaceuticals?

Marinus Pharmaceuticals' mailing address is 100 Matsonford Rd Suite 500, Radnor PA, 19087. The official website for the company is www.marinuspharma.com. The biopharmaceutical company can be reached via phone at (484) 801-4670, via email at lcaperelli@marinuspharma.com, or via fax at 203-315-0565.

This page (NASDAQ:MRNS) was last updated on 9/24/2023 by MarketBeat.com Staff

My Account -